B
Bullisch
Bullisch · 25%VXRT
$1.66
Szenariopreis
$0.320
-0.080 (-25.06%)Zum Schluss
Loading chart…
- Hoch
- 0.430
- Eröffnung
- 0.412
- Volumengewichteter Durchschnittskurs
- 0.35
- Volumen
- 24.02M
- Marktkap.
- 118.17M
- Tief
- 0.300
- Umsatz
- 8.41M
- EV/EBITDA, TTM
- -7.36
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Vaxart Inc (VXRT) beträgt -1.49, verglichen mit dem 5-Jahres-Durchschnitt von -2.68.
Alphio-AI-Kursszenarien für VXRT
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
9.007-17NewsfilterVaxart Annual Meeting Results Show Key Approvals
8.506-26NewsfilterVaxart Board's Strategic Actions to Drive Value Creation
- 9.505-09seekingalpha
Vaxart Reports Q1 2026 Earnings with Strategic Updates
- 9.505-01Newsfilter
Vaxart to Report Q1 2026 Financial Results on May 7
- 5.004-23Newsfilter
Vaxart Appoints New Board Member to Enhance Vaccine Development Expertise
VXRT FAQ – beantwortet von Alphio AI
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.